soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm

soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 Semaglutide cardiovascular outcomes align more

Name: soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 Semaglutide cardiovascular outcomes align more
Brand: ctstranslates.com
SKU: 78601138161
Price: 22.27 USD
Availability: InStock
Rating: 4.4617 (14 reviews)

SKU: 78601138161

4.5

USD22.27 USD65.27

Pay in 4 interest-free payments of $5.57 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

Description

R.Blasco ConesaM

In second to minutes, a life can be saved

Importantly, the CD20 cell surface marker is found on most malignant B cells

aleniglipron does not T2D data : Orforglipron has ACHIEVE-3 head-to-head vs oral semaglutide Company backing : Eli Lilly (orforglipron) vs Structure Therapeutics (aleniglipron) Conclusion# The oral GLP-1 small molecule space is developing into a two-horse race between aleniglipron and orforglipron